Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641444 · ClinicalTrials.gov registry record
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- 5
- Enrollment target
NCT02641444 is a clinical trial that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 5 participants.
The verdict
NCT02641444 was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out how the drugs Truvada® (tenofovir/emtricitabine), Isentress® (raltegravir), Reyataz® (atazanavir), Sustiva® (efavirenz), and Selzentry® (maraviroc) get into the intestines and the female genital tract. All of these drugs are very effective at reducing the number of HIV viruses in the blood, however it is unknown how the drugs move around inside tissues where HIV might be hiding. This study will determine specifically where in the tissue the drug and the HIV are located through the use of a new technology that takes creates a picture of the tissue. This information will help scientists determine the best way to make new drugs to target the hidden HIV in tissue.
Interventions
- PROCEDURE Blood plasma collection
- PROCEDURE Cervical and Vaginal Biopsy
- PROCEDURE Colonoscopy with Ileal and Rectal Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-04-13 |
| Est. Completion | 2017-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02641444
The ClinicalTrials.gov registry entry for NCT02641444 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood plasma collection is the first listed.
NCT02641444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02641444 about?
NCT02641444 is a clinical study titled "Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects". The purpose of this research study is to find out how the drugs Truvada® (tenofovir/emtricitabine), Isentress® (raltegravir), Reyataz® (atazanavir), Sustiva® (efavirenz), and Selzentry® (maraviroc) get into the intestines and the female genital tract. All of these drugs are very effective at reducin...
What is the current status of trial NCT02641444?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2016-04-13. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT02641444?
The interventions under investigation include: Blood plasma collection (PROCEDURE), Cervical and Vaginal Biopsy (PROCEDURE), Colonoscopy with Ileal and Rectal Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02641444?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.